A total of 703 patients with ER‐positive, HER2‐negative, T1‐3N0M0 BC were included in this study, among which 451 patients had low‐risk (RS, 0–25) and 252 patients had high‐risk (RS, 26–100) BC. This evidence concerns the gene ESR1 and breast cancer.